Vaz-Pereira S, Castro-de-Sousa JP, Martins D, et al. - In a real-world setting, researchers assessed outcomes of individuals with persistent or recurrent diabetic macular edema (DME) who switched from a short-term (dexamethasone) to a long-term (fluocinolone acetonide, FAc) corticosteroid intravitreal implant. It was a retrospective study in nine Portuguese centers. Participants in the study were 36 patients (44 eyes). Data reported that the mean duration of DME was 3.3 ± 1.9 years and mean follow-up was 8 months. Macular volume was steadily decreased from baseline to last observation carried forward, but not significantly. In patients previously treated with short-term corticosteroid implants, the FAc intravitreal implant is effective. Therefore, a single FAc implant can be considered an appropriate and tolerable therapy after suboptimal response to antiangiogenics or a short-term corticosteroid that can enhance long-term results for patients with sight-threatening DME.